Anavex Life Sciences Corp (AVXL)

[tradeherpete]

INSIGHT-Down syndrome families' fight for access to Alzheimer's trials, treatments
REUTERS 6:00 AM ET 10/10/2023

Down syndrome affects 400,000 people in the United States and more than 6 million globally. People with the condition inherit a third copy of chromosome 21, giving them an extra helping of a gene that causes them to overproduce a protein called beta amyloid.

By age 30, most individuals with Down syndrome have abnormal clumps of amyloid in their brain, and many show signs of dementia in their 40s and 50s.

Anavex would have an advantage in this market with a Rett approval, showing safety in younger patients. The mabs would need to run safety and efficacy trials, no doubt.